Literature DB >> 1555346

Resistant nonunions and partial or complete segmental defects of long bones. Treatment with implants of a composite of human bone morphogenetic protein (BMP) and autolyzed, antigen-extracted, allogeneic (AAA) bone.

E E Johnson1, M R Urist, G A Finerman.   

Abstract

Twenty-five patients with resistant nonunions including partial or complete segmental defects were treated with a composite alloimplant of human bone morphogenetic protein (h-BMP) and autolyzed, antigen-free, allogeneic bone (AAA). The series consisted of 16 females and nine males; average age was 45 years. Preoperative symptoms averaged 30 months (range, five to 83 months); 22 of 25 patients had failed multiple attempts at electrical stimulation. Twenty-three of 25 patients had an average of three prior failed surgical attempts at union (range, one to ten). There were ten segmental defects with an average length of 4 cm (range, 2-9 cm). The composite implant was incorporated as an onlay in 15 extremities and as an inlay graft supported by internal fixation in ten extremities. Seven patients received supplementary autogeneic cancellous bone grafting. Average healing time was six months (range, three to 14 months). Average follow-up time was 21 months (range, five to 82 months). Functional results were rated as excellent, 14; good, five; and fair, five. One failed to unite because of a recurrent infection. Union was obtained in 24 of 25 patients. There were five failures of the original operation that required reoperations; union eventually occurred in four of five extremities by repeat composite grafting and replacement of the failed internal fixation. Bony union between host bone and the composite implant began at an average of eight weeks postoperatively. Present results indicate that h-BMP/AAA composite implants represent adjunctive treatment of difficult nonunions. The h-BMP/AAA composite implants may be implanted in either partial or complete segmental defects of long bones.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1555346

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  12 in total

1.  In vitro and in vivo methods to determine the interactions of osteogenic cells with biomaterials.

Authors:  R O Oreffo; J T Triffitt
Journal:  J Mater Sci Mater Med       Date:  1999 Oct-Nov       Impact factor: 3.896

2.  The Otto Aufranc Award: Demineralized bone matrix around porous implants promotes rapid gap healing and bone ingrowth.

Authors:  Letitia Lim; J Dennis Bobyn; Kristian M Bobyn; Louis-Philippe Lefebvre; Michael Tanzer
Journal:  Clin Orthop Relat Res       Date:  2012-02       Impact factor: 4.176

3.  Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions.

Authors:  G E Friedlaender; C R Perry; J D Cole; S D Cook; G Cierny; G F Muschler; G A Zych; J H Calhoun; A J LaForte; S Yin
Journal:  J Bone Joint Surg Am       Date:  2001       Impact factor: 5.284

Review 4.  Growth factor delivery: how surface interactions modulate release in vitro and in vivo.

Authors:  William J King; Paul H Krebsbach
Journal:  Adv Drug Deliv Rev       Date:  2012-03-10       Impact factor: 15.470

5.  Long-term safety and efficacy of human bone morphogenetic protein (HBMP) in the treatment of resistant non-unions and failed arthrodesis.

Authors:  Arya Nick Shamie; Hamed Yazdanshenas; Eric Egan Johnson
Journal:  J Clin Orthop Trauma       Date:  2016-11-16

Review 6.  Biotechnology and bone graft substitutes.

Authors:  R A Kenley; K Yim; J Abrams; E Ron; T Turek; L J Marden; J O Hollinger
Journal:  Pharm Res       Date:  1993-10       Impact factor: 4.200

7.  Osteogenic protein-1 for long bone nonunion: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2005-04-01

Review 8.  Growth factors in bone repair.

Authors:  Valentina Devescovi; Elisa Leonardi; Gabriela Ciapetti; Elisabetta Cenni
Journal:  Chir Organi Mov       Date:  2008-11-29

9.  The Influence of Platelet-Derived Growth Factor and Bone Morphogenetic Protein Presentation on Tubule Organization by Human Umbilical Vascular Endothelial Cells and Human Mesenchymal Stem Cells in Coculture.

Authors:  Emily A Bayer; Morgan V Fedorchak; Steven R Little
Journal:  Tissue Eng Part A       Date:  2016-10-10       Impact factor: 3.845

10.  The use of growth factors and mesenchymal stem cells in orthopaedics.

Authors:  Medha Kanitkar; Hiteshkumar D Tailor; Wasim S Khan
Journal:  Open Orthop J       Date:  2011-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.